Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The investigators will assess whether the DPP-inhibitor sitagliptin will ameliorate
glucocorticoid-induced impairment of glucose metabolism and beta-cell dysfunction and thus
could be used as a prophylaxis for glucocorticoid-induced diabetes. Therefore the
investigators will administer in males with the metabolic syndrome 30 mg prednisolone daily
for two weeks and give simultaneously sitagliptin 100 mg daily. Subjects will undergo at
baseline and after two weeks of treatment several tests to assess changes in glucose
metabolism.